NCT06621810 Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
| NCT ID | NCT06621810 |
| Status | Recruiting |
| Phase | — |
| Sponsor | German Cancer Research Center |
| Condition | Melanoma (Skin Cancer) |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-12-01 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-12-01 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30). The main goals it aims to achieve are: * development of an algorithm based on dermatoscopic images, targeting skin cancer screening in vulnerable populations * development of another algorithm based on histological images, intended to be used by pathologists on lesions that are still suspicious of melanoma after dermatologic assessment * implementation of explainability methods to enable the user to better comprehend the systems' decisions, avoid biases and increase trust in these applications There is no additional time commitment for the study participants for this study, as the data used in this project will be collected in routine clinical practice anyway.
Eligibility Criteria
Inclusion Criteria: \- Exclusion Criteria: * Patients without a melanoma or nevus diagnosis * images with insufficient image quality
Contact & Investigator
Titus J Brinker, PD Dr. med
PRINCIPAL INVESTIGATOR
German Cancer Research Center
Frequently Asked Questions
Who can join the NCT06621810 clinical trial?
This trial is open to participants of all sexes, studying Melanoma (Skin Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06621810 currently recruiting?
Yes, NCT06621810 is actively recruiting participants. Contact the research team at titus.brinker@nct-heidelberg.de for enrollment information.
Where is the NCT06621810 trial being conducted?
This trial is being conducted at Tübingen, Germany, Florence, Italy, Barcelona, Spain.
Who is sponsoring the NCT06621810 clinical trial?
NCT06621810 is sponsored by German Cancer Research Center. The principal investigator is Titus J Brinker, PD Dr. med at German Cancer Research Center. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.